MXPA04003886A - Tiofen- y tiazolsulfonamidas como agentes antineoplasticos. - Google Patents

Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.

Info

Publication number
MXPA04003886A
MXPA04003886A MXPA04003886A MXPA04003886A MXPA04003886A MX PA04003886 A MXPA04003886 A MX PA04003886A MX PA04003886 A MXPA04003886 A MX PA04003886A MX PA04003886 A MXPA04003886 A MX PA04003886A MX PA04003886 A MXPA04003886 A MX PA04003886A
Authority
MX
Mexico
Prior art keywords
thiazolesulfonamides
thiopene
amd
antineoplastic agents
antineoplastic
Prior art date
Application number
MXPA04003886A
Other languages
English (en)
Spanish (es)
Inventor
Sue Grossman Cora
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MXPA04003886A publication Critical patent/MXPA04003886A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA04003886A 2001-10-25 2002-10-15 Tiofen- y tiazolsulfonamidas como agentes antineoplasticos. MXPA04003886A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35201201P 2001-10-25 2001-10-25
PCT/US2002/031568 WO2003035629A1 (en) 2001-10-25 2002-10-15 Thiopene- amd thiazolesulfonamides as antineoplastic agents

Publications (1)

Publication Number Publication Date
MXPA04003886A true MXPA04003886A (es) 2004-07-08

Family

ID=23383421

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003886A MXPA04003886A (es) 2001-10-25 2002-10-15 Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.

Country Status (33)

Country Link
US (2) US7084170B2 (enExample)
EP (1) EP1442030B1 (enExample)
JP (1) JP4464681B2 (enExample)
KR (1) KR100913471B1 (enExample)
CN (1) CN1298709C (enExample)
AR (1) AR037248A1 (enExample)
AT (1) ATE338033T1 (enExample)
AU (1) AU2002334817B2 (enExample)
BR (1) BR0212386A (enExample)
CA (1) CA2463300C (enExample)
CY (1) CY1106247T1 (enExample)
DE (1) DE60214413T2 (enExample)
DK (1) DK1442030T3 (enExample)
EA (1) EA006081B1 (enExample)
EC (1) ECSP045078A (enExample)
EG (1) EG26021A (enExample)
ES (1) ES2269816T3 (enExample)
HR (1) HRP20040371B1 (enExample)
HU (1) HUP0401638A3 (enExample)
IL (2) IL160851A0 (enExample)
MX (1) MXPA04003886A (enExample)
MY (1) MY130718A (enExample)
NO (1) NO20041316L (enExample)
NZ (1) NZ531136A (enExample)
PE (1) PE20030574A1 (enExample)
PL (1) PL208083B1 (enExample)
PT (1) PT1442030E (enExample)
SI (1) SI1442030T1 (enExample)
SV (1) SV2004001367A (enExample)
TW (1) TWI281916B (enExample)
UA (1) UA75716C2 (enExample)
WO (1) WO2003035629A1 (enExample)
ZA (1) ZA200403089B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2363396A1 (en) * 2001-06-11 2011-09-07 Virochem Pharma Inc. Thiophene derivatives as antiviral agents for flavivirus infection
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US7375131B2 (en) * 2002-06-06 2008-05-20 Smithklinebeecham Corp. NF-κB inhibitors
DE60332482D1 (de) 2002-12-10 2010-06-17 Virochem Pharma Inc Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
JP5134247B2 (ja) * 2004-09-13 2013-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド含有化合物の血管新生阻害物質との併用
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
WO2006030941A1 (ja) * 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
KR20070114774A (ko) * 2005-02-28 2007-12-04 에자이 알앤드디 매니지먼트 가부시키가이샤 술폰아미드 화합물의 혈관 신생 저해 물질과의 신규 병용
PL1859793T3 (pl) 2005-02-28 2011-09-30 Eisai R&D Man Co Ltd Nowe połączone zastosowanie związku sulfonamidowego w leczeniu choroby nowotworowej
WO2006090927A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物の摂食亢進作用
JP5030947B2 (ja) * 2005-05-13 2012-09-19 ヴァイロケム・ファーマ・インコーポレーテッド フラビウイルス感染の治療及び予防のための化合物及び方法
US7208506B2 (en) 2005-07-07 2007-04-24 Hoffmann-La Roche Inc. Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
US7625896B2 (en) * 2005-11-25 2009-12-01 Hoffman-La Roche Inc. Pyridylsulfonamide derivatives
EP2015070A4 (en) 2006-04-20 2010-04-21 Eisai R&D Man Co Ltd Novel marker for sensitivity against sulfonamide compound
US7939532B2 (en) 2006-10-26 2011-05-10 Hoffmann-La Roche Inc. Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
SG176488A1 (en) * 2006-11-15 2011-12-29 Virochem Pharma Inc Thiophene analogues for the treatment or prevention of flavivirus infections
WO2008138594A1 (en) 2007-05-16 2008-11-20 F. Hoffmann-La Roche Ag Aryl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
CN101899008B (zh) * 2010-05-20 2012-10-17 中国人民解放军第二军医大学 N-取代嘧啶磺酰基-取代苯甲酰胺类化合物及其制备药物的用途
CN103450149B (zh) * 2012-06-01 2015-10-14 中国科学院上海有机化学研究所 苯基噻吩磺酰胺类化合物及其制备方法和用途
JP6364967B2 (ja) * 2014-05-30 2018-08-01 東ソー株式会社 ジチエノベンゾジチオフェンの製造方法
CN106588868A (zh) * 2016-11-16 2017-04-26 武汉理工大学 一种2‑溴‑3‑噻吩甲酸中间体的合成方法
CN108558822B (zh) * 2018-06-01 2020-12-18 盐城锦明药业有限公司 N-((5-溴噻吩-2-基)磺酰基)-2,4-二氯苯甲酰胺的合成方法
CN110835345A (zh) * 2018-08-17 2020-02-25 中国科学院上海药物研究所 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
CN109265437A (zh) * 2018-10-19 2019-01-25 凯莱英医药集团(天津)股份有限公司 一种3-羟基噻吩-2-羧酸酯类化合物的制备方法
EP4724106A1 (en) * 2023-06-07 2026-04-15 Kræftens bekæmpelse Protacs and hyt-pd molecules for targeted protein degradation of dcaf15 and their use in the treatment of amyloidosis
WO2025031361A1 (zh) * 2023-08-09 2025-02-13 上海科技大学 磺酰胺类化合物作为制备治疗癌症药物的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA813332B (en) * 1980-06-21 1982-05-26 Pfizer Larvicides and isecticides
ZA915371B (en) * 1990-07-17 1993-03-31 Lilly Co Eli Antitumor compositions and methods of treatment
US5177074A (en) 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5169860A (en) * 1992-03-13 1992-12-08 Eli Lilly And Company Antitumor compositions and methods of treatment
ATE310738T1 (de) * 1996-07-05 2005-12-15 Us Gov Health & Human Serv Gesättigte 1,2-dithiaheterocyclische verbindungen enthaltende antivirale pharmazeutische zubereitungen
CA2267998A1 (en) 1996-10-04 1998-04-09 Eli Lilly And Company Antitumor compositions and methods of treatment
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、

Also Published As

Publication number Publication date
US20040198784A1 (en) 2004-10-07
ZA200403089B (en) 2005-04-22
UA75716C2 (en) 2006-05-15
EP1442030B1 (en) 2006-08-30
CN1575286A (zh) 2005-02-02
PT1442030E (pt) 2006-12-29
WO2003035629A1 (en) 2003-05-01
EA006081B1 (ru) 2005-08-25
US7084170B2 (en) 2006-08-01
HRP20040371A2 (en) 2004-08-31
MY130718A (en) 2007-07-31
CY1106247T1 (el) 2011-06-08
HUP0401638A3 (en) 2012-09-28
AU2002334817B2 (en) 2008-02-21
CA2463300C (en) 2011-07-19
CA2463300A1 (en) 2003-05-01
EP1442030A1 (en) 2004-08-04
ATE338033T1 (de) 2006-09-15
PE20030574A1 (es) 2003-07-03
ECSP045078A (es) 2004-06-28
IL160851A0 (en) 2004-08-31
NO20041316L (no) 2004-03-30
SV2004001367A (es) 2004-02-24
HK1068337A1 (en) 2005-04-29
KR100913471B1 (ko) 2009-08-25
HRP20040371B1 (en) 2012-07-31
HUP0401638A2 (hu) 2004-11-29
DK1442030T3 (da) 2006-12-27
EA200400582A1 (ru) 2004-08-26
PL368234A1 (en) 2005-03-21
CN1298709C (zh) 2007-02-07
TWI281916B (en) 2007-06-01
US20060223871A1 (en) 2006-10-05
IL160851A (en) 2009-11-18
US7250430B2 (en) 2007-07-31
ES2269816T3 (es) 2007-04-01
EG26021A (en) 2012-12-10
JP2005511547A (ja) 2005-04-28
PL208083B1 (pl) 2011-03-31
SI1442030T1 (sl) 2006-12-31
DE60214413D1 (de) 2006-10-12
DE60214413T2 (de) 2007-03-08
NZ531136A (en) 2006-08-31
AR037248A1 (es) 2004-11-03
KR20040062583A (ko) 2004-07-07
JP4464681B2 (ja) 2010-05-19
BR0212386A (pt) 2004-07-27

Similar Documents

Publication Publication Date Title
PL369530A1 (en) Chemical compounds
MXPA03011197A (es) Benzoilsufonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales.
GB0124627D0 (en) Novel compounds
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
JO2654B1 (en) Multiple aryl caroxa amides are useful as lipid - lowering agents
DE60112974D1 (en) Carbolinderivate
ZA200309887B (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
AU2003228770A8 (en) Substituted pyrazolopyrimidines
AU2002239344A1 (en) Pyrazolopyridines
DE602004021472D1 (en) Pyrimiidinverbindungen
MXPA05011643A (es) 5,7-diaminopirazolo[4,3-d]pirimidinas en el tratamiento de hipertension.
GB0127903D0 (en) Improvements relating to organic compounds
DE60112330D1 (en) Pyrazolopyridinderivate
IL163777A0 (en) Kinase inhibitors
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
AU2003290592A1 (en) Antitumor benzoylsulfonamides
MXPA02012493A (es) 1-aril-4-oxo, 1,4-dihidro-3-quinolincarboxamidas como agentes antivirales.
MXPA03009602A (es) Analogos de nociceptina.
MXPA04003755A (es) Endoprotesis vasculares.
SE0103710D0 (sv) Compounds
SV2003000981A (es) Fenil-heterociclil-eteres ref. pcs10973
MY128164A (en) Compounds
DE60201074D1 (en) Pyrazolopyridinderivate
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
SI1377574T1 (enExample)

Legal Events

Date Code Title Description
FG Grant or registration